Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions

HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children

(2013) U Amstutz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing

(2013) S G Leckband et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese

(2013) Ying-Kit Cheung et al.   EPILEPSIA

HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review

(2012) V L Yip et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing

(2012) M A Martin et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions

(2012) Mark McCormack et al.   PHARMACOGENOMICS

HLA-B Alleles and Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Han Chinese Population

(2011) Yi-Wu Shi et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Phenotype Standardization for Immune-Mediated Drug-Induced Skin Injury

(2011) M Pirmohamed et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans

(2011) Sae-Hoon Kim et al.   EPILEPSY RESEARCH

Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients

(2011) Yan Zhang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis

(2011) Maja Mockenhaupt   Expert Review of Clinical Immunology

Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population

(2011) Choong-Chor Chang et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

(2011) Pei Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans

(2011) Mark McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland

(2011) Qian Wang et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

HLA-B*1502 Strongly Predicts Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients with Neuropathic Pain

(2011) Kongkiat Kulkantrakorn et al.   Pain Practice

AGREE II: advancing guideline development, reporting and evaluation in health care

(2010) M. C. Brouwers et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

New Insights in Toxic Epidermal Necrolysis (Lyellʼs Syndrome)

(2010) Philippe Paquet et al.   DRUG SAFETY

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients

(2010) Nahoko Kaniwa et al.   EPILEPSIA

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population

(2010) Wichittra Tassaneeyakul et al.   EPILEPSIA

Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China

(2010) X.T. Wu et al.   EPILEPSY & BEHAVIOR

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

(2010) Takeshi Ozeki et al.   HUMAN MOLECULAR GENETICS

Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese

(2010) Shuen-Iu Hung et al.   PHARMACOGENOMICS

The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity

(2009) Sidonie Nelly Lavergne et al.   Current Opinion in Allergy and Clinical Immunology

Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum

(2009) Sandra Knowles et al.   Dermatologic Therapy

HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions

(2009) Hiroko Ikeda et al.   EPILEPSIA

Immune mediation of hypersensitivity adverse drug reactions: implications for therapy

(2009) Michael J Rieder   Expert Opinion On Drug Safety

Genetic predisposition of life-threatening antiepileptic-induced skin reactions

(2009) Wen-Hung Chung et al.   Expert Opinion On Drug Safety

Association of HLA-BFNx011502 allele and carbamazepine-inducedStevens-Johnson syndromeamong Indians

(2009) TimirY Mehta et al.   Indian Journal of Dermatology Venereology & Leprology

Oxcarbazepine-induced Stevens-Johnson Syndrome: A Case Report

(2009) Lung-Chang Lin et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population

(2008) Chaichon Locharernkul et al.   EPILEPSIA

Oxcarbazepine-induced Stevens-Johnson syndrome in a patient withHLA-B*1502genotype

(2008) Y-C Chen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE

A European study of HLA-B in Stevens???Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

(2008) Christine Lonjou et al.   Pharmacogenetics and Genomics